Medistem CEO Dr. Alan Lewis to Present at the Stem Cell Meeting on the Mesa
Medistem announced today Dr. Alan Lewis, the recently appointed CEO of Medistem, will be presenting at the Stem Cells on the Mesa meeting. The company will discuss its ongoing programs at creating effective treatments for cardiovascular diseases using the Endometrial Regenerative Cell (ERC), a stem cell derived from menstrual blood.
“The lining of the uterus is unique in its ability to create large numbers of new blood vessels monthly. We found that the cells responsible for creation of new blood vessels, the ER, are shed into the menstrual blood. The ERC have now been cleared by the FDA for clinical trials,” said Dr. Lewis. “Currently we are pursuing clinical trials in patients with heart failure and critical limb ischemia, an advanced form of peripheral artery disease. In both of these conditions we anticipate the production of new blood vessels will lead to therapeutic responses.”
The NIH has recently published that Medistem's ERC possess a unique genetic profile associated with stimulation of new blood vessel growth. The paper may be found at http://www.translational-medicine.com/content/pdf/1479-5876-10-207.pdf
“We are excited about the commercialization potential of these cells, given that one donor can generated 20,000 treatment doses,” said Thomas Ichim, President and Chief Scientific Officer of Medistem.
Medistem's presentation will be at 5:30 PM, Monday, October 29th, 2012, Location: Sanford Consortium, 2880 Torrey Pines Scenic Drive, La Jolla, CA.
The 2012 Stem Cell Meeting on the Mesa is aimed at bringing together senior members of the business development and scientific research communities in regenerative medicine to advance stem cell science into cures for debilitating diseases and injuries. The meeting features a nationally recognized Scientific Symposium attended by more than 600 leading scientists and researchers alongside the regenerative medicine industry's premier annual Investor and Partnering.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.
President and Chief Scientific Officer